Lyra Therapeutics (LYRA)
(Delayed Data from NSDQ)
$0.28 USD
+0.01 (2.67%)
Updated Sep 19, 2024 03:59 PM ET
After-Market: $0.28 0.00 (-0.36%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth D Momentum F VGM
Price, Consensus and EPS Surprise
LYRA 0.28 +0.01(2.67%)
Will LYRA be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for LYRA based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for LYRA
Lyra Therapeutics, Inc. (LYRA) Reports Q2 Loss, Tops Revenue Estimates
Esperion Therapeutics (ESPR) Reports Q2 Loss, Tops Revenue Estimates
LYRA: What are Zacks experts saying now?
Zacks Private Portfolio Services
OptiNose (OPTN) Reports Q2 Loss, Lags Revenue Estimates
Lyra Therapeutics, Inc. (LYRA) Reports Q1 Loss, Tops Revenue Estimates
Lyra Therapeutics (LYRA) Soars 6.5%: Is Further Upside Left in the Stock?
Other News for LYRA
Lyra Therapeutics still sees potential in rhinosinusitis asset despite setbacks
Lyra Therapeutics (LYRA) Receives a Hold from BTIG
Lyra Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update
LYRA Stock Earnings: Lyra Therapeutics Beats EPS, Beats Revenue for Q2 2024
Lyra Therapeutics reports Q2 EPS (74c), consensus (33c)